Benzimidazoles for inhibiting protein tyrosine kinase...

Details Benzimidazoles for inhibiting protein tyrosine kinase... Benzimidazoles for inhibiting protein tyrosine kinase...

1999-12-10

2001-04-17

Stockton, Laura L. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S338000, C514S394000

Reexamination Certificate

active

06218388

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to the inhibition of protein tyrosine kinase (PTK) mediated cellular proliferation. More specifically, this invention relates to benzimidazoles and their use in inhibiting cellular proliferation and protein tyrosine kinase enzymatic activity.
BACKGROUND OF THE INVENTION
Many disease states are characterized by the uncontrolled proliferation and differentiation of cells. These disease states encompass a variety of cell types and maladies such as cancer, atherosclerosis, restenosis, and psoriasis. Growth factor stimulation, autophosphorylation, and the phosphorylation of intracellular protein substrates are important biological events in the pathomechanisms of proliferative diseases.
In normal cells, the phosphorylation of tyrosine residues on protein substrates serves a critical function in intracellular growth signaling pathways initiated by stimulated extracellular growth factor receptors. For example, the association of growth factors such as Platelet Derived Growth Factor (PDGF), Fibroblast Growth Factor (FGF), and Epidermal Growth Factor (EGF) with their respective extracellular receptors, PDGFr, FGFr, and EGFr, activates intracellular tyrosine kinase enzyme domains of these receptors, thereby catalyzing the phosphorylation of either intracellular substrates or the receptors themselves. The phosphorylation of growth factor receptors in response to ligand binding is known as autophosphorylation.
For example, the EGF receptor has as its two most important ligands EGF and Transforming Growth Factor &agr;, (TGF&agr;). The receptors appear to have only minor functions in normal adult humans, but are implicated in the disease processes of a large portion of all cancers, especially colon and breast cancer. The closely related Erb-B2 and Erb-B3 receptors have a family of Heregulins as their major ligands, and receptor overexpression and mutation have been unequivocally demonstrated as the major risk factor in poor prognosis breast cancer.
The proliferation and directed migration of vascular smooth muscle cells (VSMC) are important components in such processes as vascular remodeling, restenosis and atherosclerosis. Platelet-derived growth factor has been identified as one of the most potent endogenous VSMC mitogens and chemoattractants. Elevated vascular mRNA expression of PDGF-A and -B chains and PDGF receptors has been observed in balloon-injured rat carotid arteries (
J. Cell. Biol.,
1990; 111:2149-2158). In this injury model, infusion of PDGF also greatly increases intimal thickening and migration of VSMC (
J. Clin. Invest.,
1992;89:507-511). Furthermore, PDGF-neutralizing antibodies significantly reduce intimal thickening following balloon injury (
Science,
1991;253: 1129-1132). Tyrphostin receptor tyrosine kinase inhibitors which block the PDGF signal transduction pathway have been shown to inhibit PDGF stimulated receptor tyrosine kinase phosphorylation in vivo in the rat cuff injury model (
Drug Develop. Res.,
1993;29:158-166).
Both acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF) have many biological activities, including the ability to promote cellular proliferation and differentiation. Direct evidence in support of FGF involvement in VSMC has been reported by Lindner and Reidy (
Proc. Natl. Acad. Sci. USA,
1991;88:3739-3743), who demonstrated that the systemic injection of a neutralizing antibody against bFGF prior to balloon angioplasty of rat carotid arteries inhibited injury-induced medial SMC proliferation by greater than 80% when measured 2 days after injury. It is likely that bFGF released from damaged cells is acting in a paracrine manner to induce VSMC growth. Recently, Lindner and Reidy (
Cir. Res.,
1993;73:589-595) demonstrated an increased expression of both mRNA for bFGF and FGFR-1 in replicating VSMCs and endothelium in en face preparations of balloon-injured rat carotid arteries. The data provides evidence that in injured arteries the ligand/receptor system of bFGF and FGFR-1 may be involved in the continued proliferative response of VSMCs leading to neointima formation.
Buchdunger, et al.,
Proc. Natl. Acad. Sci.,
Vol. 92, March 1995, 2558-2562, reported the inhibition of the PDGF signal transduction pathway both in vitro and in vivo by a PDGF receptor tyrosine protein kinase inhibitor. The compound showed antitumor activity in tumor models using astrocytoma cell lines.
Thus, EGF, PDGF, FGF, and other growth factors play pivotal roles in the pathomechanisms of cellular proliferative diseases such as cancer, atherosclerosis, and restenosis. Upon association with their respective receptors, these growth factors stimulate tyrosine kinase activity as one of the initial biochemical events leading to DNA synthesis and cell division. It thereby follows that compounds which inhibit protein tyrosine kinases associated with intracellular growth factor signal transduction pathways are useful agents for the treatment of cellular proliferative diseases. We have now discovered that certain benzimidazoles inhibit protein tyrosine kinases, and are useful in treating and preventing atherosclerosis, restenosis, and cancer.
SUMMARY OF THE INVENTION
The present invention provides a method of treating cancer, the method comprising administering to a patient having cancer a therapeutically effective amount of a compound of Formula I
wherein
Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
R
1
, R
2
, R
3
, and R
4
are each independently hydrogen, C
1
-C
6
alkyl, —OC
1
-C
6
alkyl, —OH, halogen, —CO
2
Ra, —CONR
a
R
b
, —NO
2
, —NR
a
R
b
, —COC
1
-C
6
alkyl, —CHO, —CN, —SO
2
C
1
-C
6
alkyl,
—OCH
2
CH(OH)CH
2
OH, —O(CH
2
)
n
NR
a
R
b
, —O(CH
2
)
n
N-morpholino, —SH, —SC
1
-C
6
alkyl, or —S(CH
2
)
n
NR
a
R
a
, or R
2
and R
3
together can form a cycloalkyl ring that may contain one or more heteroatom;
R
a
and R
b
are each independently hydrogen or C
1
-C
6
alkyl, n is 0 to 5, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
The present invention also provides a method of treating or preventing restenosis, the method comprising administering to a patient having restenosis or at risk of having restenosis a therapeutically effective amount of a compound of Formula I
wherein
Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
R
1
, R
2
, R
3
, and R
4
are each independently hydrogen, C
1
-C
6
alkyl, —OC
1
-C
6
alkyl, —OH, halogen, —CO
2
R
a
, —CONR
a
R
b
, —NO
2
, —NR
a
R
b
, —COC
1
-C
6
alkyl, —CHO, —CN, —SO
2
C
1
-C
6
alkyl,
—CH
2
CH(OH)CH
2
OH, —O(CH
2
)
n
NR
a
R
b
, —O(CH
2
)
n
N-morpholino, —SH, —SC
1
-C
6
alkyl, or —S(CH
2
)
n
NR
a
R
b
, or R
2
and R
3
together can form a cycloalkyl ring that may contain one or more heteroatom;
R
a
and R
b
are each independently hydrogen or C
1
-C
6
alkyl, n is 0 to 5, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
In another embodiment, the present invention provides a method of treating atherosclerosis, the method comprising administering to a patient having atherosclerosis a therapeutically effective amount of a compound of Formula I
wherein
Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
R
1
, R
2
, R
3
, and R
4
are each independently hydrogen, C
1
-C
6
alkyl, —OC
1
-C
6
alkyl, —OH, halogen, —CO
2
R
a
, —CONR
a
R
b
, —NO
2
, —NR
a
R
b
, —COC
1
-C
6
alkyl, —CHO, —CN, —SO
2
C
1
-C
6
alkyl,
—OCH
2
CH(OH)CH
2
OH, —O(CH
2
)
n
NR
a
R
b
, or —O(CH
2
)
n
N-morpholino, —SH, —SC
1
-C
6
alkyl, or —S(CH
2
)
n
NR
a
R
a
, or R
2
and R
3
together can form a cycloalkyl ring that may contain one or more heteroatom;
R
a
and R
b
are each independently hydrogen or C
1
-C
6
alkyl, n is 0 to 5, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
Also provided is a method of treating psoriasis, the method comprising administering to a patient having psoriasis a therapeutically effective amount of a compound of Formula I
wherein
Ar is aryl, substituted aryl, heteroaryl, or substituted heteroa

Affiliated with

Also associated with

Rating

Benzimidazoles for inhibiting protein tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzimidazoles for inhibiting protein tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazoles for inhibiting protein tyrosine kinase... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2517504